The objective of this study is to evaluate the safety and feasability of transauricular vagus nerve stimulation for patients with chronic whiplash associated disorder using a take-home device, a variety of physical measurements, and questionnaires. Approximately 50% of people with chronic whiplash-associated disorders (WAD) continue to report the presence of symptoms 12 months post-injury. These symptoms include high levels of pain and disability as well as psychological symptoms such as anxiety. The nervous system may also be affected, specifically the autonomic nervous system which is responsible for regulating heart rate and blood pressure. An important part of the autonomic system is the vagus nerve, which helps regulate pain and stress responses. Treatment of this nerve via transauricular vagal nerve stimulation (taVNS) has been shown to improve health outcomes in many pain conditions such as chronic low back pain and postural tachycardia syndrome. TaVNS works by sending mild electrical pulses through the ear. This project aims to explore whether or not taVNS can help people with chronic whiplash feel better. Our first goal is to evaluate the safety and feasibility of this type of study. We are interested in learning how many people with chronic WAD participate in the study and how many complete the full treatment, as well as ensuring that the treatment does not cause any serious side effects. Our additional goal is to evaluate the effects of taVNS on neck pain intensity and associated disability, pain sensitivity, heart rate variability, blood pressure, quality of life, anxiety, and depression as measured be questionnaires and physical assessments, as compared to those assigned to the sham treatment.

This study wants to validate a scale called the Brief COPE. This scale measures coping strategies in individuals with Parkinson's Disease (PD) and their care partners. Coping refers to the thoughts and behaviors people use to manage the challenges and stressors they face. Proper coping strategies are crucial for maintaining a good quality of life for people with PD. The Brief COPE is a questionnaire that assesses coping methods for dealing with stressful life events. It has been used in various disorders and populations, but not in PD and care partners. By validating this scale, researchers want to provide a tool to understand and test coping strategies. The study will involve 200 participants, including 100 patients and 100 care partners. The outcomes of this study will contribute to understanding better the coping strategies in PD. To improve the quality of care and support for patients and their care partners.

ABP 692 is an investigational medication that is being developed to be similar to ocrelizumab. The OAK Study will test the pharmacokinetics (how the body absorbs, distributes, and processes the medication), pharmacodynamics (how the medication affects the body), clinical effects, and safety of the investigational ABP 692, compared to the FDA- and European Medicines Agency (EMA)-approved Ocrevus® (ocrelizumab) in people with relapsing-remitting multiple sclerosis. Eligible participants will be assigned randomly (by chance) to receive one of the following treatments: • Group A: 3 infusions of ABP 692. • Group B: 2 infusions of US-ocrelizumab and 1 infusion of ABP 692. • Group C: 3 infusions of EU-ocrelizumab.

In this study we are collecting information about access to genetic testing and genetic care for ALS in Canada. This is a questionnaire study in which we will collect demographic and health information. This will inform how genetic care for ALS is provided across Canada and whether there are opportunities to recommend additional training, support, or resources to certain regions.

We are retrospectively looking a the relationship between mental health, cognition and headaches in the patient with brain injuries that present to the Calgary Brain Injury Program. As well, we are prospectively, looking at exercise behaviours following brain injury in patients that present to the Calgary Brain Injury program and Chronic Pain Centre.

This study is looking for healthy controls to participate in an MRI scan. Healthy controls will be chosen based on age and sex to match a group of patients already recruited for the study. This study requires volunteers to participate in two MRI scans that will be conducted at the Foothills Hospital location. The first scan will be after study enrollment and the second will be a follow-up scan a year later.

We are investigating if biosensor can accurately measure blood biomarkers of concussion. Concussion diagnoses and prognoses are currently reliant on subjective measures. A biosensor that can objectively measure concussion could supplement subjective measures. This would allow early diagnosis or recovery monitoring to reduce recovery times. All participants in this study will complete initial visit measures upon enrolment. These include questionnaires (15 minutes) and a blood draw (5 minutes). Participants with concussion will return for follow-up visits at 2, 6, and 12 weeks after injury or until recovery. They will also complete a daily online symptom survey (2 minutes), and be given access to concussion education resources. Participants with a muscular or skeletal injury will only complete initial visit measures.

Do you have adult-onset idiopathic dystonia and pain? A better understanding of pain in dystonia is needed to help develop specific treatment options. Our goal is to develop a tool to identify and quantify pain in dystonia. The study consists of one to three short visits to the Movement Disorders Program, Department of Clinical Neurosciences, University of Calgary.

This study will implement the iCARE-PD model which consists of an approach by health providers, to support patients through the challenges of their disease and facilitate their access to health resources in the community. The iCARE-PD promotes self-management skills (i.e. e.g. to improve swallowing and speech by joining speech therapy sessions and doing vocal exercises at home, to improve balance by joining a exercises group or a fall prevention clinic) that will simplify the use of available specialized services with little increase in resources and cost. To provide more effective integration of care, technology will be explored to share health information using electronically delivered study questionnaires.

CGRP monoclonal antibodies (mAbs) have been effective for many migraine patients who previously failed the standard treatments. The purpose of this research study is to assess early results of all four currently available CGRP mAbs (fremanezumab, galcanezumab, erenumab and eptinezumab), with the focus on their tolerability and safety. Also, this study will try to answer the important question of whether non-responders to treatment with one of the CGRP mAbs benefit from switch to another other Ab or not.